Skip to main content
Top

06-06-2024 | Diabetes | REVIEW

Review Article – Diabetes Technology in the Hospital: An Update

Authors: Margaretha M. Visser, Roman Vangoitsenhoven, Pieter Gillard, Chantal Mathieu

Published in: Current Diabetes Reports

Login to get access

Abstract

Purpose of Review

There have been many developments in diabetes technology in recent years, with continuous glucose monitoring (CGM), insulin pump therapy (CSII) and automated insulin delivery (AID) becoming progressively accepted in outpatient diabetes care. However, the use of such advanced diabetes technology in the inpatient setting is still limited for several reasons, including logistical challenges and staff training needs. On the other hand, hospital settings with altered diet and stress-induced hyperglycemia often pose challenges to tight glycemic control using conventional treatment tools. Integrating smarter glucose monitoring and insulin delivery devices into the increasingly technical hospital environment could reduce diabetes-related morbidity and mortality. This narrative review describes the most recent literature on the use of diabetes technology in the hospital and suggests avenues for further research.

Recent Findings

Advanced diabetes technology has the potential to improve glycemic control in hospitalized people with and without diabetes, and could add particular value in certain conditions, such as nutrition therapy or perioperative management. Taken together, CGM allows for more accurate and patient-friendly follow-up and ad hoc titration of therapy. AID may also provide benefits, including improved glycemic control and reduced nursing workload.

Summary

Before advanced diabetes technology can be used on a large scale in the hospital, further research is needed on efficacy, accuracy and safety, while implementation factors such as cost and staff training must also be overcome.
Literature
2.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53. https://doi.org/10.1016/S0140-6736(98)07019-6.CrossRef UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53. https://​doi.​org/​10.​1016/​S0140-6736(98)07019-6.CrossRef
13.
go back to reference American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119–31. https://doi.org/10.2337/dc09-9029.CrossRef American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119–31. https://​doi.​org/​10.​2337/​dc09-9029.CrossRef
18.
19.
go back to reference • Tian T, Aaron RE, Yeung AM, Huang J, Drincic A, Seley JJ, et al. Use of Continuous Glucose Monitors in the Hospital: The Diabetes Technology Society Hospital Meeting Report 2023. J Diabetes Sci Technol. 2023;17:1392–418. https://doi.org/10.1177/19322968231186575. (Very recent report on the progress of hospital use of continuous glucose monitoring (including automated insulin delivery), summarizing not only the potential benefits but also the unmet needs in the use of diabetes technology in the hospital)CrossRefPubMed • Tian T, Aaron RE, Yeung AM, Huang J, Drincic A, Seley JJ, et al. Use of Continuous Glucose Monitors in the Hospital: The Diabetes Technology Society Hospital Meeting Report 2023. J Diabetes Sci Technol. 2023;17:1392–418. https://​doi.​org/​10.​1177/​1932296823118657​5. (Very recent report on the progress of hospital use of continuous glucose monitoring (including automated insulin delivery), summarizing not only the potential benefits but also the unmet needs in the use of diabetes technology in the hospital)CrossRefPubMed
32.
go back to reference Galindo RJ, Migdal AL, Davis GM, Urrutia MA, Albury B, Zambrano C, et al. Comparison of the FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System and Point-of-Care Capillary Glucose Testing in Hospitalized Patients With Type 2 Diabetes Treated With Basal-Bolus Insulin Regimen. Diabetes Care. 2020;43:2730–5. https://doi.org/10.2337/dc19-2073.CrossRefPubMedPubMedCentral Galindo RJ, Migdal AL, Davis GM, Urrutia MA, Albury B, Zambrano C, et al. Comparison of the FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System and Point-of-Care Capillary Glucose Testing in Hospitalized Patients With Type 2 Diabetes Treated With Basal-Bolus Insulin Regimen. Diabetes Care. 2020;43:2730–5. https://​doi.​org/​10.​2337/​dc19-2073.CrossRefPubMedPubMedCentral
63.
78.
go back to reference Sobel SI, Augustine M, Donihi AC, Reider J, Forte P, Korytkowski M. Safety and efficacy of a peri-operative protocol for patients with diabetes treated with continuous subcutaneous insulin infusion who are admitted for same-day surgery. Endocr Pract. 2015;21:1269–76. https://doi.org/10.4158/EP15727.OR.CrossRefPubMed Sobel SI, Augustine M, Donihi AC, Reider J, Forte P, Korytkowski M. Safety and efficacy of a peri-operative protocol for patients with diabetes treated with continuous subcutaneous insulin infusion who are admitted for same-day surgery. Endocr Pract. 2015;21:1269–76. https://​doi.​org/​10.​4158/​EP15727.​OR.CrossRefPubMed
82.
go back to reference • Spanakis EK, Cook CB, Kulasa K, Aloi JA, Bally L, Davis G, et al. A Consensus Statement for Continuous Glucose Monitoring Metrics for Inpatient Clinical Trials. J Diabetes Sci Technol. 2023;17:1527–52. https://doi.org/10.1177/19322968231191104. (Consensus statement for continuous glucose monitoring metrics for inpatient clinical trials, describing metrics for research on the use of continuous glucose monitoring in the hospital setting)CrossRefPubMed • Spanakis EK, Cook CB, Kulasa K, Aloi JA, Bally L, Davis G, et al. A Consensus Statement for Continuous Glucose Monitoring Metrics for Inpatient Clinical Trials. J Diabetes Sci Technol. 2023;17:1527–52. https://​doi.​org/​10.​1177/​1932296823119110​4. (Consensus statement for continuous glucose monitoring metrics for inpatient clinical trials, describing metrics for research on the use of continuous glucose monitoring in the hospital setting)CrossRefPubMed
Metadata
Title
Review Article – Diabetes Technology in the Hospital: An Update
Authors
Margaretha M. Visser
Roman Vangoitsenhoven
Pieter Gillard
Chantal Mathieu
Publication date
06-06-2024
Publisher
Springer US
Published in
Current Diabetes Reports
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-024-01545-3
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine